Economic impact of migraine and other episodic headaches in France: data from the GRIM2000 study

Pradalier, André; Auray, Jean-Paul; El Hasnaoui, Abdelkader; Alzahouri, Kazem; Dartigues, Jean-François; Duru, Gérard; Henry, Patrick; Lantéri-Minet, Michel; Lucas, Christian; Chazot, Guy; Gaudin, Anne-François; Pradalier, André; Dartigues, Jean-François; Duru, Gérard; Lantéri-Minet, Michel; Gaudin, Anne-François
October 2004
PharmacoEconomics;2004, Vol. 22 Issue 15, p985
Academic Journal
journal article
Background: Migraine is a prevalent and incapacitating condition that affects individuals in the prime of their productive life, thus generating an economic burden for both society and healthcare systems. The direct annual healthcare costs of migraine in France were assessed over 10 years ago, and the current study updates these figures.Objective: The objective of this study was to determine the economic cost (primarily direct costs) of migraine and other episodic headache in France based on a general population survey of headache, the GRIM2000 (Groupe de Researche Interdisciplinaire sur la Migraine).Design: From a representative general population sample of 10,585 individuals aged > or = 15 years in France in 1999, 1486 individuals experiencing headaches were identified and interviewed regarding healthcare resource consumption in the previous 6 months. By applying unit costs to the resource data, costings (in 1999 values) were determined for physician consultations, hospitalisation, medication use and diagnostic/laboratory tests, and evaluated from a healthcare system perspective. Information on absenteeism and lost productivity was derived from the Migraine Disability Assessment Score (MIDAS) questionnaire.Results: The prevalence of migraine (including migrainous disorder) was determined to be 17%. Total annual direct healthcare costs were estimated to be Euros 128 per individual with migraine in 1999, corresponding to Euros 1044 million when extrapolated to all individuals experiencing migraine and aged > or = 15 years. Around two-thirds of this cost accrued to the social security system (Euros 698 million; Euros 85 per individual). The total annual direct cost of other forms of episodic headache was much lower at Euros 28 per individual (social security cost Euros 18); with a prevalence of 9.2%, the annual national direct cost for other forms of episodic headache totalled Euros 124 million. The principal cost element was physician consultations. However, it was found that many individuals had never consulted a physician for their headaches, and self-medication contributed substantially to the medication costs (the second greatest cost factor for migraine). The cost per individual rose steeply with increasing severity of headache.Conclusions: The direct healthcare costs of migraine do not seem to have risen significantly over the past decade. A small minority of individuals with more severe headaches consume most of the healthcare resources devoted to migraine, while most individuals generate relatively low direct costs. The total annual direct costs in France for migraine are almost 10-fold higher than those of other episodic headache.


Related Articles

  • The economic burden of migraine to society. Ferrari, M.D. // PharmacoEconomics;1998, Vol. 13 Issue 6, p667 

    The financial burden of migraine on society comprises direct costs, associated with medical care, and indirect costs, caused by absence from work and reduced productivity. Recent studies have revealed that direct costs are generally relatively low in Europe, but are much higher in North America,...

  • Migraine costs sizeable, with or without comorbidity.  // PharmacoEconomics & Outcomes News;8/14/2004, Issue 459, p7 

    Discusses research being done on the medical costs for both children and adults with migraine. Reference to a study by J. Pesa and M. J. Lage, published in the June 2004 issue of "Headache"; Medical costs of adults with comorbid anxiety, depression, or both; Comparison of medical costs for...

  • Medicare Part D: CMS's Process and Policy for Enrolling New Dual-Eligible Beneficiaries: GAO-07-1022T. King, Kathleen M. // GAO Reports;6/21/2007, p1 

    Under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA), dual-eligible beneficiaries--individuals with both Medicare and Medicaid coverage--have their drug costs covered under Medicare Part D rather than under state Medicaid programs. The MMA requires the Centers...

  • Measuring Outcomes And Efficiency In Medicare Value-Based Purchasing. Tompkins, Christopher P.; Higgins, Aparna R.; Ritter, Grant A. // Health Affairs;2009 Supplement 1, Vol. 28, pW251 

    The Medicare program may soon adopt value-based purchasing (VBP), in which hospitals could receive incentives that are conditional on meeting specified performance objectives. The authors advocate for a market-oriented framework and direct measures of system-level value that are focused on...

  • Medicare payment rates will drop 4.3% in 2006.  // Urology Times;9/1/2005, Vol. 33 Issue 11, p4 

    Announces the details of the proposed Medicare Physician Fee Schedule by the Centers for Medicare and Medicaid in the U.S. Proposition of a rule that would lower medical care payment rates; Revisions on payment policies under the proposed rule; Percentage of the reduction required by a statutory...

  • Implications for ACOs of Variations in Spending Growth. McWilliams, J. Michael; Song, Zirui // New England Journal of Medicine;5/10/2012, Vol. 366 Issue 19, pN.PAG 

    The authors explore the implications of variations in spending growth on the Medicare Pioneer and Shared Savings Accountable Care Organization (ACO) programs. They note that geographic variations in spending growth may cause ACO in any hospital-referral regions (HRR) to gain or lose financially...

  • Should Drug Prices Be Negotiated Under Part D Of Medicare? And If So, How? Frank, Richard G.; Newhouse, Joseph P. // Health Affairs;Jan/Feb2008, Vol. 27 Issue 1, p33 

    Medicare's Part D prescription drug benefit has offered affordable coverage to millions of elderly Americans since its January 2006 implementation. A great deal of concern has been expressed about whether drugs are being purchased in a cost-effective manner. Many believe that the government...

  • Changes In Medicaid Prescription Volume And Use In The Wake Of Medicare Part D Implementation. Bruen, Brian K.; Miller, Laura M. // Health Affairs;Jan/Feb2008, Vol. 27 Issue 1, p196 

    Implementation of the Medicare drug benefit resulted in a major shift of prescription drug spending from Medicaid to Medicare. Data indicate that Medicaid programs experienced substantial changes in the volume and types of prescriptions used by enrollees. Medicaid prescription volume and total...

  • Drug-price escalation is likely to slow. Toth, David // Fairfield County Business Journal;4/25/2005, Vol. 44 Issue 17, p25 

    The article reports that the Center for Medicare and Medicaid Services (CMS) has stated in a study that although prescription drug spending is at an all-time high, the growth may be slowing and that trend is likely to continue. The high cost of using a brand name medication when a generic brand...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics